Recent Finacing
Recent Raise
Foghorn Therapeutics, founded via Flagship VentureLabs in 2016, uses a proprietary Gene Traffic Control platform and discovery engine to develop chromatin-regulation-targeted therapeutics across oncology, neurology, and immunology.
